Allogene Therapeutics Inc. (ALLO)’s Financial Results Comparing With Synthetic Biologics Inc. (NYSEAMERICAN:SYN)

Both Allogene Therapeutics Inc. (NASDAQ:ALLO) and Synthetic Biologics Inc. (NYSEAMERICAN:SYN) are each other’s competitor in the Biotechnology industry. Thus the compare of their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Allogene Therapeutics Inc. 28 0.00 N/A -2.05 0.00
Synthetic Biologics Inc. 1 0.00 N/A -3.44 0.00

Table 1 demonstrates Allogene Therapeutics Inc. and Synthetic Biologics Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 provides us the return on equity, return on assets and net margins of both companies.

Net Margins Return on Equity Return on Assets
Allogene Therapeutics Inc. 0.00% 0% 0%
Synthetic Biologics Inc. 0.00% 0% -141.5%


The Current Ratio of Allogene Therapeutics Inc. is 17.5 while its Quick Ratio stands at 17.5. The Current Ratio of rival Synthetic Biologics Inc. is 8.6 and its Quick Ratio is has 8.6. Allogene Therapeutics Inc. is better equipped to clear short and long-term obligations than Synthetic Biologics Inc.

Analyst Ratings

The next table highlights the shown recommendations and ratings for Allogene Therapeutics Inc. and Synthetic Biologics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Allogene Therapeutics Inc. 0 0 2 3.00
Synthetic Biologics Inc. 0 0 0 0.00

Allogene Therapeutics Inc.’s upside potential currently stands at 60.20% and an $45 consensus target price.

Insider & Institutional Ownership

The shares of both Allogene Therapeutics Inc. and Synthetic Biologics Inc. are owned by institutional investors at 52.4% and 22.2% respectively. About 2% of Allogene Therapeutics Inc.’s share are owned by insiders. Comparatively, insiders own roughly 0.1% of Synthetic Biologics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Allogene Therapeutics Inc. -6.18% 10.1% -10.58% -6.73% 0% 6.05%
Synthetic Biologics Inc. -2.01% -6.35% -7.67% -29.75% -93.82% 5.36%

For the past year Allogene Therapeutics Inc. was more bullish than Synthetic Biologics Inc.


On 6 of the 6 factors Allogene Therapeutics Inc. beats Synthetic Biologics Inc.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is headquartered in South San Francisco, California.

Synthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates in Phase III development include SYN-010, which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase) that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), antibiotic-associated diarrhea (AAD), and the emergence of antimicrobial resistance (AMR). The company is also developing SYN-007 and SYN-006 for the prevention of CDI and AAD; SYN-005, a monoclonal antibody therapy for the prevention and treatment of pertussis; SYN-200 for the treatment of phenylketonuria; and SYN-020, an oral dosage form of intestinal alkaline phosphatase. It has collaboration agreements with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.